Peptide · Fact sheet
Humanin
Also known as HN · MT-RNR2 peptide · S14G-humanin (experimental analog)
Humanin is a naturally occurring mitochondrial-derived peptide studied in cell survival, neurodegeneration, metabolism, and aging. No humanin drug product is FDA approved, and there is no convincing clinical trial evidence that taking a humanin product improves cognition or extends healthy life.
What is Humanin?
Humanin is a short peptide encoded within the mitochondrial MT-RNR2 region and involved in stress-response and cell-survival signaling.
Researchers also study more potent synthetic analogs such as S14G-humanin; results from an analog, a cell experiment, or a blood-level association do not prove a treatment effect from native humanin.
Benefits people look for
Cell and animal models report neuroprotective, metabolic, retinal, cardiovascular, and anti-apoptotic signals.
Human genetics and biomarker studies link Humanin biology with cognitive aging or disease, but those associations are not trials of a humanin medicine.
What the evidence supports
- Laboratory and animal studies report protection from selected toxic or metabolic stresses.
- A human genetic association study linked a variant associated with lower circulating humanin to cognitive aging, but did not test humanin treatment.
All research areas
- Neuroprotection in laboratory and animal models
- Cognitive aging associations
- Metabolic and insulin-signaling biology
- Retinal and cardiovascular cell protection
- Muscle-atrophy mechanisms in cultured human cells
- Neurodegenerative-disease mechanisms
- Mitochondrial and metabolic stress
- Healthy-aging and muscle-protection research
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- A reliable human treatment safety profile has not been established.
- Analog identity, exposure, immune reactions, off-target signaling, and long-term effects remain poorly defined.
- Products sold outside an approved application add quality, purity, sterility, strength, and labeling uncertainty.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Mostly animal or lab researchThe treatment literature is dominated by cell and animal studies. Human studies are primarily observational, genetic, or biomarker research and cannot show that administering humanin improves outcomes.
Selected research to read
Cell, animal, and human genetic-association findings; not a human treatment trial.
Multi-species preclinical and observational study that does not establish a human longevity treatment.
Laboratory study in retinal pigment epithelial cells supporting preclinical mechanisms.
Laboratory study in human muscle cells, not a clinical trial in people.
FDA approval & research status
No humanin or humanin-analog product is FDA approved. Human therapeutic development has not produced a mature clinical program establishing benefit for cognition, neurodegeneration, metabolism, or aging.
No FDA-approved use is documented in the records summarized on this page.
Preclinical and observational research
Humanin research is dominated by cell, animal, genetic, and biomarker studies. The page references do not show a mature human treatment program or FDA approval.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Whether humanin or an analog can improve any clinical outcome in people
- Which molecule, formulation, and target population would be appropriate for trials
- Short- and long-term safety
- Whether observational links with aging or cognition are causal
The takeaway
Humanin connects mitochondria, cell survival, and brain-aging research in fascinating ways. Today, however, it is a preclinical research subject—not a proven cognitive, muscle, or longevity therapy.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1pubmedHumanin and cognitive aging study
Cell, animal, and human genetic-association findings; not a human treatment trial.
- 2pubmedHumanin lifespan and healthspan research
Multi-species preclinical and observational study that does not establish a human longevity treatment.
- 3pubmedHumanin retinal-cell protection study
Laboratory study in retinal pigment epithelial cells supporting preclinical mechanisms.
- 4pubmedHumanin and MOTS-c in cultured human muscle cells
Laboratory study in human muscle cells, not a clinical trial in people.